Ignite Creation Date:
2024-05-06 @ 2:40 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04397978
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2020-05-11
Brief Title:
Local Ablative Therapy for Patients With Multiple 4-10 Brain Metastases
Sponsor:
Universitaire Ziekenhuizen KU Leuven
Organization:
Universitaire Ziekenhuizen KU Leuven
Study Overview
Official Title:
Local Ablative Therapy for Patients With Multiple 4-10 Brain Metastases
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAT-MUM
Brief Summary:
To observe the quality of life QOL and to report on toxicity and outcome parameters after the repeated use of local ablative therapy LAT ie stereotactic radiotherapy SRT for patients with multiple 4-10 brain metastases
Detailed Description:
Phase IV prospective non-randomized observational trial registry trial for patients with a DS-GPA 15 or an estimated life expectancy of 3 months and an established diagnosis on dedicated brain MRI of 4-10 BM of any solid primary tumor
We plan to deliver a local ablative therapy LAT ie SRT in 1 to 5 fractions on visible BM and post-surgical cavities if applicable
Our primary aim is to provide quality of life QOL data and our secondary aim is to report on several toxicity and outcome parameters for this patient cohort
We plan to deliver a local ablative therapy LAT ie SRT in 1 to 5 fractions on visible BM and post-surgical cavities if applicable
Our primary aim is to provide quality of life QOL data and our secondary aim is to report on several toxicity and outcome parameters for this patient cohort
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None